Provectus Biopharmaceuticals (PVCT) CEO holds 52.4M shares, 11.61% stake
Provectus Biopharmaceuticals, Inc. said an SEC Schedule 13D amendment updates Edward Pershing’s stake. According to the filing, Pershing beneficially owns 52,441,275 common shares, 11.61%, via common holdings, Series D-1 preferred conversions, and exercisable options. The filing also details $7.5125M in convertible notes and recent note conversions/purchases.
How this was made
The 30-second read
Why it matters
The key tradable angle is the disclosed conversion pathway from notes and preferred into common shares, which can create dilution expectations and influence risk premium.
Market read
A new 13D amendment provides updated beneficial ownership (11.61%) and specific conversion math from notes and Series D-1 preferred into common shares.
What to watch
Traders should separate beneficial ownership from actual near-term float impact, and monitor whether conversions translate into market selling versus continued holding.
Background
The article is an SEC Schedule 13D Amendment No. 3 describing changes to Items 3 and 5, including convertible note issuance, conversions into Series D-1 preferred, and resulting common stock issuable.
Ticker impact
PVCT discloses via a Schedule 13D amendment that the reporting person beneficially owns 11.61% and holds convertible notes convertible into millions of shares.
Near-term impact is likely limited, but conversion-related dilution risk could cap rallies; watch for follow-on financing or conversion activity.
This is a primary SEC filing update (13D amendment) with concrete ownership and conversion mechanics, but it does not announce a new financing, deal, or immediate conversion event beyond routine note conversions already described.
Market effects
Limited sector read-across; this is company-specific capital structure and ownership disclosure.
None indicated.
None indicated.
Counterpoint
The stake increase may reflect confidence and could support sentiment if conversions are orderly and not tied to distress financing.
Key entities
- issuerPROVECTUS BIOPHARMACEUTICALS, INC.
Subject of the Schedule 13D amendment; common stock and convertible instruments referenced.
- reporting_personEdward Pershing
Reporting person whose beneficial ownership and transactions are detailed in the amendment.
